ELUT Elutia Inc. Class A Common Stock Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
06:51
Jan 13
Jan 13
ELUT debt-free, FDA catalyst, multi-bagger potential
Elutia reported preliminary Q4 2025 revenue of ~$3.3M (up 16% YoY), repaid all $26.9M secured debt, and ended 2025 with $36.3M cash plus $8M from escrow, giving ~$44M liquidity against a ~$30M market cap. The company is targeting the $1.5B breast reconstruction market with NXT-41, aiming to solve the 15-25% infection rate via antibiotic-eluting matrices, with an FDA filing in H1 2026 and anticipated clearance in H2 2026. The author sees multi-bagger potential if Nasdaq compliance is regained and FDA clearance is achieved, with analyst targets of $2.00-$6.00 versus a ~$0.70 price. Main risk implied is regulatory and compliance execution.
HIGH
About ELUT Investor Commentary
Across the available history and selected sources, Buzzberg tracks ELUT (Elutia Inc. Class A Common Stock) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Impossible-Hair1343.